# OnCo record paper-ratify-midostaurin-nejm-2017 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-ratify-midostaurin-nejm-2017/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-ratify-midostaurin-nejm-2017" ;
  schema:name "RATIFY: midostaurin added to chemotherapy for acute myeloid leukaemia with a FLT3 mutation"@en ;
  schema:description "Adding the FLT3 inhibitor midostaurin to standard induction and consolidation chemotherapy, then as maintenance, lengthened survival in adults under 60 with FLT3-mutated acute myeloid leukaemia, the first targeted drug to do so."@en ;
  schema:url <https://onco.cc/key-papers/paper-ratify-midostaurin-nejm-2017/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:citation <https://doi.org/10.1056/NEJMoa1614359>, <https://pubmed.ncbi.nlm.nih.gov/28644114/> ;
  schema:sameAs <https://doi.org/10.1056/NEJMoa1614359> ;
  schema:datePublished "2017"^^xsd:gYear ;
  schema:author "Stone RM, Mandrekar SJ, Sanford BL, et al." ;
  onco:cancers <https://onco.cc/cancers/aml-flt3/> ;
  onco:drugs <https://onco.cc/drugs/midostaurin/> ;
  onco:trials <https://onco.cc/trials/ratify/> ;
  onco:journals <https://onco.cc/journals/nejm/> .